Adrenal masses: Characterization with in vivo proton MR spectroscopy - Initial experience

Radiology

Volumn 245, Issue 3, 2007, Pages 788-797

  Faria, Juliano F ^a   Goldman, Suzan M ^a   Szejnfeld, Jacob ^a   Melo, Homero ^a   Kater, Cláudio ^a   Kenney, Philip ^a   Huayllas, Martha P ^a   Demarchi, Guilherme ^a   Francisco, Viviane V ^a   Andreoni, Cássio ^a   Srougi, Miguel ^a   Ortiz, Valdemar ^a   Abdalla, Nitamar ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE; CREATINE; LIPID;

ADRENAL CORTEX ADENOMA; ADRENAL CORTEX CARCINOMA; ADRENAL METASTASIS; ADRENAL TUMOR; ADULT; ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; FEMALE; HUMAN; IMAGING SYSTEM; MAJOR CLINICAL STUDY; MALE; METABOLITE; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RECEIVER OPERATING CHARACTERISTIC;

ADENOMA; ADRENAL GLAND NEOPLASMS; ADRENOCORTICAL CARCINOMA; ADULT; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; PHEOCHROMOCYTOMA; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS;

EID: 36248929486     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiol.2453061854     Document Type: Article

References (42)

1. Caoili EM, Korobkin M, Francis IR, Cohan RH, Dunnick NR. Delayed enhanced CT of lipid poor adrenal adenomas. AJR Am J Roentgenol 2000;175:1411-1415.
2. Caoili EM, Korobkin M, Francis IR, et al. Adrenal masses: characterization with combined unenhanced and delayed enhanced CT. Radiology 2002;222:629-633.
3. Rescinito G, Zandrino F, Cittadini G Jr, Santacroce E, Giasotto V, Neumaier CE, Characterization of adrenal adenomas and metastases: correlation between non-enhanced computed tomography and chemical shift magnetic resonance imaging. Acta Radiol 2006;47:71-76.
4. Goldman SM, Coelho RD, Freire Filho Ede O, et al. Imaging procedures in adrenal pathology. Arq Bras Endocrinol Metabol 2004; 48:592-611.
5. Maurea S, Mainolli C, Bazzicalupo L, et al. Imaging of adrenal tumors using FDG PET: comparison of benign and malignant lesions. AJR Am J Roentgenol 1999;173:25-29.
6. Mackie GC, Shulkin BL, Ribeiro RC, et al. Use of 18F-deoxyfluoroglucose positron emission tomography in evaluating locally recurrent and metastatic adrenocortical carcinoma. J Clin Endocrinol Metab 2006;91: 2665-2671.
7. Haider MA, Ghai S, Jhaveri K, Lockwood G. Chemical shift MR imaging of hyperattenuating (>10 HU) adrenal masses: does if still have a role? Radiology 2004;231:711-716.
8. Israel GM, Korobkin M, Wang C, Hecht EN, Krinsky GA. Comparison of non-enhanced CT and chemical shift MRI in evaluating lipid-rich adrenal adenomas. AJR Am J Roentgenol 2004;183:215-219.
9. Savci G, Yazici Z, Sahin N, Akgoz S, Tuncel E. Value of chemical shift subtraction MRI in characterization of adrenal masses. AJR Am J Roentgenol 2006;186:130-135.
10. Paulsen SD, Nghiem HV, Korobkin M, Caoilli EM, Higgins EJ. Changing role of imaging guided percutaneous biopsy of adrenal masses: evaluation of 50 adrenal biopsies, AJR Am J Roentgenol 2004;182:1033-1037.
11. Park BK, Kim B, Ko K, Jeong SY, Kwon GY. Adrenal masses falsely diagnosed as adenomas on non-enhanced and delayed contrast-enhanced computed tomography: pathological correlation. Eur Radiol 2006;16:642-647.
12. Blake MA, Krishnamoorthy SK, Boland GW, et al. Low-density pheochromocytoma on CT: a mimicker of adrenal adenoma. AJR Am J Roentgenol 2003;181:1663-1668.
13. Blake MA, Kalra MK, Sweeney AT, et al. Distinguishing benign from malignant adrenal masses: multi-detector row CT protocol with 10-minute delay. Radiology 2006;238: 578-585.
14. Szolar DH, Korobkin M, Reittner P, et al. Adrenocortical carcinomas and adrenal pheochromocytomas: mass and enhancement loss evaluation at delayed contrast-enhanced CT. Radiology 2005;234:479-485.
15. Rutter A, Hugenholtz H, Saunders JK, Smith IC. Classification of brain tumors by ex vivo III NMR spectroscopy. J Neurochem 1995; 64:1655-1661.
16. Rand SD, Prost R, Haughton V, et al. Accuracy of single voxel proton MR spectroscopy in distinguishing neoplastic from nonneoplastic brain lesions. AJNR Am J Neuroradiol 1997;18:1695-1704.
17. Bitsch A, Behm H, Vougioukas V, et al. Inflammatory CNS demyelination: histopathologic correlation with in vivo quantitative proton spectroscopy. AJNR Am J Neuroradiol 1999;20:1619-1627.
18. Majós C, Alonso J, Aguilera C, et al. Adult primitive neuroectodermal tumor: proton MR spectroscopic findings with possible application for differential diagnosis. Radiology 2002;225:556-566.
19. Kugel H, Heindel W, Ernestus RI, Bunke J, Mesnil R, Friedmann G. Human brain tumors: spectral patterns detected with localized 1H-MR spectroscopy. Radiology 1992;183:701-709.
20. Poptani H, Gupta RK, Roy R, Pandey R, Jain VK, Chhabra DK. Characterization of intracranial mass lesions with in vivo proton MR spectroscopy. AJNR Am J Neuroradiol 1995; 16:1593-1603.
21. Adamson AJ, Rand SD, Prost RW, Kim TA, Schultz C, Haughton VM. Focal brain lesions: effect of single voxel proton MR spectroscopic findings on treatment decisions. Radiology 1998;209:73-78.
22. Meyerand ME, Pipas JM, Mamourian A, Tosteson TD, Dunn JF. Classification of biopsy confirmed brain tumors using single-voxel MR spectroscopy. AJNR Am J Neuroradiol 1999;20:117-123.
23. Stadlbauer A, Gruber S, Nimsky C, et al. Preoperative grading of gliomas by using metabolite quantification with high-spatial-resolution proton MR spectroscopic imaging. Radiology 2006;238:958-969.
24. Swindle P, McCredie S, Russell P, et al. Pathologic characterization of human prostate tissue with proton MR spectroscopy. Radiology 2003;228:144-151.
25. Mackinnon WB, Huschtscha L, Dent K, Hancock R, Paraskeva C, Mountford CE. Correlation of cellular differentiation in human colorectal carcinoma and adenoma cell lines with metabolite profiles determined by 1H magnetic resonance spectroscopy. Int J Cancer 1994;59:248-261.
26. Wang CK, Li CW, Hsieh TJ, Chien SH, Liu GC, Tsai KB. Characterization of bone and soft-tissue tumors with in vivo 1H-MR spectroscopy: initial results. Radiology 2004; 232:599-605.
27. Schellinger D, Lin CS, Fertikh D, et al. Normal lumbar vertebrae: anatomic, age, and sex variance in subjects at proton MR spectroscopy - initial experience. Radiology 2000;215:910-916.
28. Singer S. New diagnostic modalities in soft tissue sarcoma. Semin Surg Oncol 1999;17: 11-22.
29. Mukherji SK, Schiro S, Castillo M, et al. Proton MR spectroscopy of squamous cell carcinoma of the upper aerodigestive tract: in vitro characteristics. AJNR Am J Neuroradiol 1996;17:1485-1490.
30. Yeung DK, Cheung HS, Tse GM. Human breast lesions: characterization with contrast-enhanced in vivo proton MR spectroscopy - initial results. Radiology 2001;220: 40-46.
31. Maheshwari SR, Mukherji SK, Neelon B, et al. The choline creatine ratio in five benign neoplasms: comparison with squamous cell carcinoma by use of in vitro MR spectroscopy. AJNR Am J Neuroradiol 2000;21: 1930-1935.
32. Lim AK, Patel N, Gedroyc WM, Blomley MJ, Hamilton G, Taylor-Robinson SD. Hepatocellular adenoma: diagnostic difficulties and novel imaging techniques. Br J Radiol 2002; 75:695-699.
33. King AD, Yeung DK, Ahuja AT, et al. Salivary gland tumors at in vivo proton MR spectroscopy. Radiology 2005;237:563-569.
34. Hom JJ, Coakley FV, Simko JP, et al. Prostate cancer: endorectal MR imaging and MR spectroscopic imaging - distinct true positive results from chance detected lesions. Radiology 2006;238:192-199.
35. Leroy-Willig A, Bittoun J, Luton JP, et al. In vivo MR spectroscopic imaging of adrenal glands: distinction between adenomas and carcinomas larger than 15 mm based on lipid content. AJR Am J Roentgenol 1989;153:771-773.
36. Allen JR, Prost RW, Griffith OW, Erickson SJ, Erickson AB. In vivo proton (H1) magnetic resonance spectroscopy for cervical carcinoma. Am J Clin Oncol 2001;24;522-529.
37. Elsayes KM, Mukundan G, Narra VR, et al. Adrenal masses: MR imaging features with pathologic correlation. RadioGraphics 2004;24(suppl 1):S73-S86.
38. Blake MA, Kalra MK, Maher MM, et al. Pheochromocytoma: an imaging chameleon. RadioGraphics 2004;24(suppl 1):S87-S99.
39. Magalhaes A, Godfrey W, Shen Y, Hu J, Smith W. Proton magnetic resonance spectroscopy of brain tumors correlated with pathology. Acad Radiol 2005;12:51-57.
40. King AD, Yeung DK, Ahuja AT, Leung SF, Tse GM, van Hasselt AC. In vivo proton MR spectroscopy of primary and nodal nasopharyngeal carcinoma. AJNR Am J Neuroradiol 2004;25:484-490.
41. Wajchenberg BL, Pereira MA, Medonca BB, et al. Adrenocortical carcinoma. Cancer 2000;88:711-736.
42. Gonen O, Gruber S, Li BS, Mlynárik V, Moser E. Multivoxel 3D proton spectroscopy in the brain at 1.5 versus 3.0 T: signal to noise ratio and resolution comparison. AJNR Am J Neuroradiol 2001;22:1727-1731.